Discover comprehensive details about Mycophenolate Mofetil, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated ...

TORONTO, June 4 /PRNewswire/ -- The 12-month results from a multicenter trial monitoring CellCept(R) (mycophenolate mofetil) in combination with calcineurin inhibitors (CNIs) in renal transplantation ...

Embryo-fetal toxicity; rule out pregnancy with serum or urine pregnancy test immediately before starting therapy, then another test 8–10 days later. Repeat pregnancy tests during routine follow-up ...

♦Contraindicated to pregnant women and patients with known hypersensitivity. It should not be co-administered with Proton Pump Inhibitors (PPIs).

Please provide your email address to receive an email when new articles are posted on . Patients receiving mycophenolate mofetil combination therapies saw increased seroconversion after a third dose ...

Renal and Urology News, a trusted source of medical news and feature content for healthcare providers, offers clinicians insight into the latest research to inform clinical practice and improve ...

June 9, 2006 — The U.S. Food and Drug Administration (FDA) has approved orphan drug status for mycophenolate mofetil in the treatment of pemphigus vulgaris; second-generation antisense drug for the ...

CellCept (mycophenolate mofetil) is a prescription drug used to prevent organ rejection after certain organ transplants. CellCept’s cost may depend on factors such as your dosage, whether you have ...

Seattle, May 25 – Monitoring the level of CellCept® (mycophenolate mofetil) in a patient's blood in the months following an organ transplant may enable physicians to identify the precise amount of ...